NPC's Jon Campbell to Speak at US ACCESS Forum 2026

Look for NPC's Chief Science Officer Jon Campbell at this year's US ACCESS Forum in New Orleans, LA. Learn more in the session details below. 

Thursday, February 12th | 2:30 PM - 3:45 PM

WORKSHOP: The Need for Speed: Navigating MFP, MFN, and Pricing Pressure with AI-Driven Scenario Planning

Speakers: 

• Leigh Ann Bruhn, Partner, Access Infinity
• Jon Campbell, Chief Science Officer, National Pharmaceutical Council
  Session Details

Session Details:

U.S. market access is entering a new era defined by unprecedented speed of change and pricing scrutiny. Policies like Maximum Fair Price (MFP) and Most-Favored Nation (MFN) provisions are reshaping the landscape, demanding that Value, Access, and Pricing leaders embrace proactive, data and analytics driven strategies.

This interactive workshop will explore how AI-enabled scenario planning is transforming decision-making. Through real-world analytical examples, workshop leaders will demonstrate how advanced forecasting models combine statistical rigor with machine learning (Large Language Model) to predict pricing, and stress-test strategies before policies fully materialize. The will examine a specific case study centered on a set of brands spanning across therapeutic areas, including oncology and autoimmune disease, and walk through how AI-powered analytics can:

• Integrate multiple data streams (HTA publications, clinical trial outcomes, economic indicators, competitive landscape, disease attributes) into actionable forecasting insights
• Model MFN-driven price floors and their ripple effects on U.S. contracting strategies
• Generate scenario comparisons that uncover hidden vulnerabilities and opportunities in portfolio planning.

Attendees will engage in facilitated small group exercises applying these frameworks to their own portfolios and developing rapid-response playbooks that support agile and informed decision-making.

Friday, February 13th | 2:30 PM - 3:30 PM

Plenary Session: Shaping Global Policy and Access in an Interconnected World

Speakers:

• Antti Kourula, VP Global Head of Market Access, CSL
• Sarah Emond, President and Chief Executive Officer, Institute for Clinical and Economic Review (ICER)
• Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
• Jon Campbell, Chief Science Officer, National Pharmaceutical Council

Session Details:
Across markets, access leaders face intense pressure to balance affordability, evidence expectations, and continued investment in innovation. Policy actions taken in one region increasingly influence decisions in others, creating a global ripple effect that manufacturers, payers, and policymakers must navigate together.

This plenary brings together leaders from key advocacy and policy bodies to examine how the next wave of reforms in the United States and Europe will shape global access norms and organizational strategy across the sector.

Discussion themes include:

• Global policy drivers shaping 2026 and beyond, including IRA implementation, MFN proposals, JCA, EU HTA, and evolving value frameworks
• How U.S. affordability initiatives are influencing international pricing expectations
• The growing tension between innovation incentives and affordability pressures
• Coordination among advocacy bodies (BIO, PhRMA, EFPIA) on aligned global policy stances
• Secondary and tertiary global impacts of domestic actions such as IRA, EU HTA rollouts, tariffs, and manufacturing policy
• Practical opportunities for cross-stakeholder collaboration that strengthen access, investment, and sustainable affordability